# A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

> **NCT05975268** · PHASE3 · COMPLETED · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 747 (actual)

## Conditions studied

- Moderate to Severe Chronic Plaque Psoriasis

## Interventions

- **BIOLOGICAL:** JS005 (recombinant humanized monoclonal antibody against IL-17A)

## Key facts

- **NCT ID:** NCT05975268
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-28
- **Primary completion:** 2025-08-20
- **Final completion:** 2025-09-03
- **Target enrollment:** 747 (ACTUAL)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05975268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05975268, "A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05975268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*